ANALYST REVIEW 001 Medtech🇵🇱
Chitomed PSA
Read the analysis
before you invest
An independent review of Chitomed’s Series B on Emiteo. Biomaterials that help the body regrow bone and soft tissue. We examine the valuation, revenue and risks.
- Pre-money valuation
- €6.39M
- Maximum raise
- €1.12M
- Price per share
- €6.81
- Offer closes
- 23 Nov 2026
Risk warning: investing in startups carries a high risk of losing your entire investment. This report is for information only and is not investment advice, an offer or a recommendation to invest.
Independent research & disclaimer
Kingscrowd Europe conducts this analysis independently and is not affiliated with Chitomed or Emiteo. The analysis is based on information publicly shared online, including company disclosures and offering materials, as available on the date stated in the report. These sources have not been independently audited or verified and may contain errors, omissions or outdated information.
Although reasonable care is taken in preparing this research, Kingscrowd Europe does not warrant its accuracy, completeness or currency. Opinions and estimates may change without notice. Readers should verify material facts, review the official offering documents and seek independent professional advice before making an investment decision. To the extent permitted by applicable law, Kingscrowd Europe accepts no liability for losses arising from reliance on this report; nothing in this disclaimer excludes liability that cannot lawfully be excluded.
Questions or spotted an error? Contact info@kingscrowd.eu.